About the Authors

Thomas R. Laws

Affiliation Biomedical Sciences Dept, Defence Science and Technology laboratory (DSTL) Porton Down, Salisbury, United Kingdom

Michelle Nelson

Affiliation Biomedical Sciences Dept, Defence Science and Technology laboratory (DSTL) Porton Down, Salisbury, United Kingdom

Cecile Bonnafous

Affiliation Innate Pharma, Marseille, France

Helene Sicard

Affiliation Innate Pharma, Marseille, France

Christopher Taylor

Affiliation Biomedical Sciences Dept, Defence Science and Technology laboratory (DSTL) Porton Down, Salisbury, United Kingdom

Francisco Javier Salguero

Affiliation Animal Health and Veterinary Laboratory Agency (AHVLA), Weybridge, United Kingdom

Timothy P. Atkins

Affiliation Biomedical Sciences Dept, Defence Science and Technology laboratory (DSTL) Porton Down, Salisbury, United Kingdom

Petra C. F. Oyston

Affiliation Biomedical Sciences Dept, Defence Science and Technology laboratory (DSTL) Porton Down, Salisbury, United Kingdom

Caroline A. Rowland

carowland@dstl.gov.uk

Affiliation Biomedical Sciences Dept, Defence Science and Technology laboratory (DSTL) Porton Down, Salisbury, United Kingdom

Competing Interests

The authors have the following interests: Co-authors Cecile Bonnafous and Helene Sicard are employed by Innate Pharma. Innate Pharma holds, or have held, the following patents relating to material pertinent to this article, (Phosphoantigens for regulating an immune response [WO 2004050096 A3], Phosphoantigen salts of organic bases and methods for their crystallization [WO 2007039635 A3], Improved methods of using phosphoantigens for the treatment of diseases [WO 2010049438 A3], New class of gamma delta t cells activators and use thereof [WO 2005054258 A3], Compositions comprising interleukin-2 and gamma-delta T cell activator and uses thereof [EP 1426052 B1], Phosphonates useful as modulators of T-γ-9-δ-2 activity [US 8017596 B2]). In addition, Cecile Bonnafous and Helene Sicard own stock in Innate Pharma. Co-authors Thomas Laws, Michelle Nelson, Chrisopher Taylor, Tim Atkins, Petra Oyston and Caroline Rowland is employed by Dstl. Dstl previously held the following patents relating to material pertinent to this article, (Treatment [WO 2010086617 A2], Phosphoantigens for the treatment of Burkholderia infections [WO 2010086617 A3]) There are no further patents, products in development or marketed products to declare. This does not alter their adherence to all the PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: TRL CAR PCFO TPA MN. Performed the experiments: TRL CAR MN CT. Analyzed the data: TRL. Contributed reagents/materials/analysis tools: TRL MN HS CB FJS. Wrote the paper: TRL CAR.